Nutrition therapy in esophageal cancer—Consensus statement of the Gastroenterological Society of Taiwan

M. J. Chen, I. C. Wu, Y. J. Chen, T. E. Wang, Y. F. Chang, C. L. Yang, W. C. Huang, W. K. Chang, B. S. Sheu, M. S. Wu, J. T. Lin, C. H. Chu

研究成果: Article

5 引文 (Scopus)

摘要

A number of clinical guidelines on nutrition therapy in cancer patients have been published by national and international societies; however, most of the reviewed data focused on gastrointestinal cancer or non-cancerous abdominal surgery. To collate the corresponding data for esophageal cancer (EC), a consensus panel was convened to aid specialists from different disciplines, who are involved in the clinical nutrition care of EC patients. The literature was searched using MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and the ISI Web of Knowledge. We searched for the best evidence pertaining to nutrition therapy in the case of EC. The panel summarized the findings in 3 sections of this consensus statement, based on which, after the diagnosis of EC, an initial distinction is made between the patients, as follows: (1) Assessment; (2) Therapy in patients with resectable disease; patients receiving chemotherapy or chemoradiotherapy prior to resection, and patients with unresectable disease, requiring chemoradiotherapy or palliative therapy; and (3) Formula. The resulting consensus statement reflects the opinions of a multidisciplinary group of experts, and a review of the current literature, and outlines the essential aspects of nutrition therapy in the case of EC. The statements are: Patients with EC are among one of the highest risk to have malnutrition. Patient generated suggestive global assessment is correlated with performance status and prognosis. Nutrition assessment for patients with EC at the diagnosis, prior to definitive therapy and change of treatment strategy are suggested and the timing interval can be two weeks during the treatment period, and one month while the patient is stable. Patients identified as high risk of malnutrition should be considered for preoperative nutritional support (tube feeding) for at least 7–10 days. Various routes for tube feedings are available after esophagectomy with similar nutrition support benefits. Limited intrathoracic anastomotic leakage postesophagectomy can be managed with intravenous antibiotics and self-expanding metal stent (SEMS) or jejunal tube. Enteral nutrition in patients receiving preoperative chemotherapy or chemoradiation provides benefits of maintaining weight, decreasing toxicity, and preventing treatment interruption. Tube feeding or SEMS can offer nutrition support in patients with unresectable esophageal cancer, but SEMS is not recommended for those with neoadjuvant chemoradiation before surgery. Enteral immunonutrition may preserve lean body mass and attenuates stress response after esophagectomy. Administration of glutamine may decrease the severity of chemotherapy induced mucositis. Enteral immunonutrition achieves greater nutrition status or maintains immune functions during concurrent chemoradiation.

原文English
文章編號doy016
期刊Diseases of the Esophagus
31
發行號8
DOIs
出版狀態Published - 2018 一月 1

指紋

Nutrition Therapy
Taiwan
Esophageal Neoplasms
Enteral Nutrition
Stents
Esophagectomy
Metals
Chemoradiotherapy
Drug Therapy
Malnutrition
Small Intestine
Therapeutics
Anastomotic Leak
Mucositis
Nutrition Assessment
Gastrointestinal Neoplasms
Nutritional Support
Glutamine
Nutritional Status
Palliative Care

All Science Journal Classification (ASJC) codes

  • Gastroenterology

引用此文

Chen, M. J., Wu, I. C., Chen, Y. J., Wang, T. E., Chang, Y. F., Yang, C. L., ... Chu, C. H. (2018). Nutrition therapy in esophageal cancer—Consensus statement of the Gastroenterological Society of Taiwan. Diseases of the Esophagus, 31(8), [doy016]. https://doi.org/10.1093/dote/doy016
Chen, M. J. ; Wu, I. C. ; Chen, Y. J. ; Wang, T. E. ; Chang, Y. F. ; Yang, C. L. ; Huang, W. C. ; Chang, W. K. ; Sheu, B. S. ; Wu, M. S. ; Lin, J. T. ; Chu, C. H. / Nutrition therapy in esophageal cancer—Consensus statement of the Gastroenterological Society of Taiwan. 於: Diseases of the Esophagus. 2018 ; 卷 31, 編號 8.
@article{e86af4149f2540a6a138a13dd3c1a578,
title = "Nutrition therapy in esophageal cancer—Consensus statement of the Gastroenterological Society of Taiwan",
abstract = "A number of clinical guidelines on nutrition therapy in cancer patients have been published by national and international societies; however, most of the reviewed data focused on gastrointestinal cancer or non-cancerous abdominal surgery. To collate the corresponding data for esophageal cancer (EC), a consensus panel was convened to aid specialists from different disciplines, who are involved in the clinical nutrition care of EC patients. The literature was searched using MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and the ISI Web of Knowledge. We searched for the best evidence pertaining to nutrition therapy in the case of EC. The panel summarized the findings in 3 sections of this consensus statement, based on which, after the diagnosis of EC, an initial distinction is made between the patients, as follows: (1) Assessment; (2) Therapy in patients with resectable disease; patients receiving chemotherapy or chemoradiotherapy prior to resection, and patients with unresectable disease, requiring chemoradiotherapy or palliative therapy; and (3) Formula. The resulting consensus statement reflects the opinions of a multidisciplinary group of experts, and a review of the current literature, and outlines the essential aspects of nutrition therapy in the case of EC. The statements are: Patients with EC are among one of the highest risk to have malnutrition. Patient generated suggestive global assessment is correlated with performance status and prognosis. Nutrition assessment for patients with EC at the diagnosis, prior to definitive therapy and change of treatment strategy are suggested and the timing interval can be two weeks during the treatment period, and one month while the patient is stable. Patients identified as high risk of malnutrition should be considered for preoperative nutritional support (tube feeding) for at least 7–10 days. Various routes for tube feedings are available after esophagectomy with similar nutrition support benefits. Limited intrathoracic anastomotic leakage postesophagectomy can be managed with intravenous antibiotics and self-expanding metal stent (SEMS) or jejunal tube. Enteral nutrition in patients receiving preoperative chemotherapy or chemoradiation provides benefits of maintaining weight, decreasing toxicity, and preventing treatment interruption. Tube feeding or SEMS can offer nutrition support in patients with unresectable esophageal cancer, but SEMS is not recommended for those with neoadjuvant chemoradiation before surgery. Enteral immunonutrition may preserve lean body mass and attenuates stress response after esophagectomy. Administration of glutamine may decrease the severity of chemotherapy induced mucositis. Enteral immunonutrition achieves greater nutrition status or maintains immune functions during concurrent chemoradiation.",
author = "Chen, {M. J.} and Wu, {I. C.} and Chen, {Y. J.} and Wang, {T. E.} and Chang, {Y. F.} and Yang, {C. L.} and Huang, {W. C.} and Chang, {W. K.} and Sheu, {B. S.} and Wu, {M. S.} and Lin, {J. T.} and Chu, {C. H.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/dote/doy016",
language = "English",
volume = "31",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "8",

}

Chen, MJ, Wu, IC, Chen, YJ, Wang, TE, Chang, YF, Yang, CL, Huang, WC, Chang, WK, Sheu, BS, Wu, MS, Lin, JT & Chu, CH 2018, 'Nutrition therapy in esophageal cancer—Consensus statement of the Gastroenterological Society of Taiwan', Diseases of the Esophagus, 卷 31, 編號 8, doy016. https://doi.org/10.1093/dote/doy016

Nutrition therapy in esophageal cancer—Consensus statement of the Gastroenterological Society of Taiwan. / Chen, M. J.; Wu, I. C.; Chen, Y. J.; Wang, T. E.; Chang, Y. F.; Yang, C. L.; Huang, W. C.; Chang, W. K.; Sheu, B. S.; Wu, M. S.; Lin, J. T.; Chu, C. H.

於: Diseases of the Esophagus, 卷 31, 編號 8, doy016, 01.01.2018.

研究成果: Article

TY - JOUR

T1 - Nutrition therapy in esophageal cancer—Consensus statement of the Gastroenterological Society of Taiwan

AU - Chen, M. J.

AU - Wu, I. C.

AU - Chen, Y. J.

AU - Wang, T. E.

AU - Chang, Y. F.

AU - Yang, C. L.

AU - Huang, W. C.

AU - Chang, W. K.

AU - Sheu, B. S.

AU - Wu, M. S.

AU - Lin, J. T.

AU - Chu, C. H.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A number of clinical guidelines on nutrition therapy in cancer patients have been published by national and international societies; however, most of the reviewed data focused on gastrointestinal cancer or non-cancerous abdominal surgery. To collate the corresponding data for esophageal cancer (EC), a consensus panel was convened to aid specialists from different disciplines, who are involved in the clinical nutrition care of EC patients. The literature was searched using MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and the ISI Web of Knowledge. We searched for the best evidence pertaining to nutrition therapy in the case of EC. The panel summarized the findings in 3 sections of this consensus statement, based on which, after the diagnosis of EC, an initial distinction is made between the patients, as follows: (1) Assessment; (2) Therapy in patients with resectable disease; patients receiving chemotherapy or chemoradiotherapy prior to resection, and patients with unresectable disease, requiring chemoradiotherapy or palliative therapy; and (3) Formula. The resulting consensus statement reflects the opinions of a multidisciplinary group of experts, and a review of the current literature, and outlines the essential aspects of nutrition therapy in the case of EC. The statements are: Patients with EC are among one of the highest risk to have malnutrition. Patient generated suggestive global assessment is correlated with performance status and prognosis. Nutrition assessment for patients with EC at the diagnosis, prior to definitive therapy and change of treatment strategy are suggested and the timing interval can be two weeks during the treatment period, and one month while the patient is stable. Patients identified as high risk of malnutrition should be considered for preoperative nutritional support (tube feeding) for at least 7–10 days. Various routes for tube feedings are available after esophagectomy with similar nutrition support benefits. Limited intrathoracic anastomotic leakage postesophagectomy can be managed with intravenous antibiotics and self-expanding metal stent (SEMS) or jejunal tube. Enteral nutrition in patients receiving preoperative chemotherapy or chemoradiation provides benefits of maintaining weight, decreasing toxicity, and preventing treatment interruption. Tube feeding or SEMS can offer nutrition support in patients with unresectable esophageal cancer, but SEMS is not recommended for those with neoadjuvant chemoradiation before surgery. Enteral immunonutrition may preserve lean body mass and attenuates stress response after esophagectomy. Administration of glutamine may decrease the severity of chemotherapy induced mucositis. Enteral immunonutrition achieves greater nutrition status or maintains immune functions during concurrent chemoradiation.

AB - A number of clinical guidelines on nutrition therapy in cancer patients have been published by national and international societies; however, most of the reviewed data focused on gastrointestinal cancer or non-cancerous abdominal surgery. To collate the corresponding data for esophageal cancer (EC), a consensus panel was convened to aid specialists from different disciplines, who are involved in the clinical nutrition care of EC patients. The literature was searched using MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and the ISI Web of Knowledge. We searched for the best evidence pertaining to nutrition therapy in the case of EC. The panel summarized the findings in 3 sections of this consensus statement, based on which, after the diagnosis of EC, an initial distinction is made between the patients, as follows: (1) Assessment; (2) Therapy in patients with resectable disease; patients receiving chemotherapy or chemoradiotherapy prior to resection, and patients with unresectable disease, requiring chemoradiotherapy or palliative therapy; and (3) Formula. The resulting consensus statement reflects the opinions of a multidisciplinary group of experts, and a review of the current literature, and outlines the essential aspects of nutrition therapy in the case of EC. The statements are: Patients with EC are among one of the highest risk to have malnutrition. Patient generated suggestive global assessment is correlated with performance status and prognosis. Nutrition assessment for patients with EC at the diagnosis, prior to definitive therapy and change of treatment strategy are suggested and the timing interval can be two weeks during the treatment period, and one month while the patient is stable. Patients identified as high risk of malnutrition should be considered for preoperative nutritional support (tube feeding) for at least 7–10 days. Various routes for tube feedings are available after esophagectomy with similar nutrition support benefits. Limited intrathoracic anastomotic leakage postesophagectomy can be managed with intravenous antibiotics and self-expanding metal stent (SEMS) or jejunal tube. Enteral nutrition in patients receiving preoperative chemotherapy or chemoradiation provides benefits of maintaining weight, decreasing toxicity, and preventing treatment interruption. Tube feeding or SEMS can offer nutrition support in patients with unresectable esophageal cancer, but SEMS is not recommended for those with neoadjuvant chemoradiation before surgery. Enteral immunonutrition may preserve lean body mass and attenuates stress response after esophagectomy. Administration of glutamine may decrease the severity of chemotherapy induced mucositis. Enteral immunonutrition achieves greater nutrition status or maintains immune functions during concurrent chemoradiation.

UR - http://www.scopus.com/inward/record.url?scp=85059028763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059028763&partnerID=8YFLogxK

U2 - 10.1093/dote/doy016

DO - 10.1093/dote/doy016

M3 - Article

C2 - 29860406

AN - SCOPUS:85059028763

VL - 31

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 8

M1 - doy016

ER -